GeoVax is currently working on a vaccine to combat hemorrhagic fever viruses, such as Ebola.
To that end, the organization entered into an agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for a Cooperative Research and Development Agreement for Material Transfer.
“We are truly excited to be able to collaborate with researchers at USAMRIID regarding the characterization of our tetravalent vaccine (TV) candidate against Ebola Zaire, Ebola Sudan, Marburg and Lassa fever viruses,” Farshad Guirakhoo, GeoVax's senior vice president of research and development, said.
The agreement will allow both parties to share information and material for the vaccine. The vaccine will be used to combat all forms of Ebola.
“Media attention on the threat of Ebola virus -- or on hemorrhagic fever viruses in general -- has obviously waned since the 2014-15 Ebola epidemic has been contained,” Robert McNally, GeoVax president and CEO, said. “However, that does not eliminate the need for a safe, effective and broadly protective vaccine to protect against the future outbreaks that are certain to occur. Hemorrhagic fever viruses fatal to humans are endemic to Africa where reservoirs remain in animal hosts such as bats, and as the 2014-15 Ebola epidemic showed, these viruses may quickly spread beyond the borders where the outbreak first begins.”
McNally is optimistic about future results and looks forward to further testing.
“We have demonstrated 100 percent protection in small animal models and are confident further testing in non-human primates will prove our vaccine is robust and worthy of continuing to move forward,” he said.